Teledermatology in the US: Access, Limitations, and Quality of Care

Teledermatology applies telecommunications technology to the delivery of dermatologic evaluation and, in some cases, treatment management — without requiring a patient to be physically present in a clinic. This page covers how these services are structured, what regulatory frameworks govern them, where they perform well, and where their diagnostic limits are recognized in the clinical literature. Understanding these boundaries matters because teledermatology affects both access equity and patient safety in meaningful, measurable ways.

Definition and scope

Teledermatology is a subspecialty application of telemedicine in which dermatologic images, patient histories, and clinical data are transmitted electronically between a patient (or referring provider) and a dermatologist. The American Academy of Dermatology (AAD) recognizes teledermatology as a formal care modality and has published position statements outlining standards for its practice.

The scope of teledermatology in the US is shaped partly by the regulatory environment governing telemedicine more broadly. The regulatory context for dermatology — including state medical board licensure requirements, payer coverage rules, and prescribing restrictions — defines which services can legally be delivered remotely and under what conditions. As of the Public Health Emergency (PHE) waivers issued under the COVID-19 pandemic, the Centers for Medicare & Medicaid Services (CMS) expanded reimbursement for telehealth services; many of those expansions remained under legislative review by Congress.

Teledermatology encompasses two architecturally distinct delivery models:

Store-and-forward (SAF): Photographs and clinical data are captured, stored, and transmitted asynchronously to a dermatologist for later review. This model does not require simultaneous patient and provider availability and is commonly used in federally qualified health centers (FQHCs) and Veterans Health Administration (VHA) facilities.
Live interactive (synchronous): A real-time video consultation between patient and provider, equivalent in structure to a traditional office visit conducted over a HIPAA-compliant video platform.

A hybrid model combining both is used in some integrated health systems, where a referring primary care provider captures images and provides them alongside a synchronous handoff or message thread.

How it works

In a store-and-forward workflow, a patient or a referring clinician submits standardized photographs — typically taken against a neutral background under consistent lighting — along with a structured history that includes lesion duration, prior treatments, and relevant systemic conditions. The dermatologist reviews this packet asynchronously and returns a consult note, often within 24 to 72 hours depending on program protocols.

In synchronous teledermatology, both parties connect via a video platform that meets the requirements of the Health Insurance Portability and Accountability Act (HIPAA). The provider conducts a structured visual examination and verbal history. This model supports real-time clarification but is limited by consumer-grade camera resolution, variable lighting, and the inability to palpate lesions.

Quality benchmarks for teledermatology image capture have been outlined by the AAD in its teledermatology toolkit, which specifies recommended camera resolution, focal distances, and background conditions. The VHA, operating one of the largest store-and-forward teledermatology programs in the US, published outcome data showing agreement rates between teledermatology and in-person dermatology diagnoses ranging from approximately 70% to over 90%, depending on condition complexity and image quality (VA Teledermatology Program).

Prescriptions issued via teledermatology are subject to the Ryan Haight Online Pharmacy Consumer Protection Act and applicable state laws; controlled substances face additional restrictions that vary by jurisdiction.

Common scenarios

Teledermatology performs most reliably for visually distinctive, morphologically stable conditions where image quality is adequate and a biopsy is not immediately required. Common clinical applications include:

Acne assessment and management — A condition with defined grading scales (such as the Investigator Global Assessment scale) that translate well to photographic review; acne causes and treatment guidance can be initiated without tactile examination in most mild-to-moderate presentations.
Psoriasis monitoring — Stable plaque psoriasis types and management in patients with an established diagnosis are candidates for interval teledermatology follow-up rather than in-person visits.
Eczema flare evaluation — Eczema and atopic dermatitis flare patterns can be assessed remotely for treatment adjustments in patients whose baseline has been characterized in person.
Rosacea follow-up — Erythema, telangiectasia, and papulopustular components of rosacea diagnosis and care are visually assessable under good image conditions.
Triage of pigmented lesions — Store-and-forward teledermatology is used in some public health systems to risk-stratify pigmented lesions prior to scheduling in-person dermoscopy or biopsy, reducing unnecessary appointments for low-risk findings.

Dermatologists operating on platforms covered by the nationaldermatologyauthority.com home resource routinely encounter teledermatology as a first point of patient contact, particularly in rural or underserved geographic areas where in-person dermatology appointment wait times can exceed 60 days in documented shortage areas (Health Resources and Services Administration, HRSA Shortage Area data).

Decision boundaries

Teledermatology has defined limitations that the AAD and clinical researchers have documented across peer-reviewed literature. These are not software limitations but inherent constraints of remote visual examination.

Conditions requiring in-person evaluation include:

Any lesion with clinical features suggesting melanoma recognition and risk — dermoscopy, tactile assessment, and potential same-visit biopsy are required; a store-and-forward photograph cannot substitute.
Suspected inflammatory dermatoses where texture, induration, warmth, or lymph node assessment is diagnostically necessary.
Full-body skin cancer screening guidelines — total-body skin examination cannot be replicated at adequate quality through consumer-device cameras.
Contact dermatitis cases where formal patch testing for allergies is indicated.
Pediatric presentations with uncertain morphology, where pediatric dermatology conditions may require physical measurement and developmental context.

Prescribing constraints further limit teledermatology's scope: isotretinoin, classified as a teratogenic agent and managed under the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program administered by the FDA, has specific requirements that may not be fully satisfiable via remote-only encounters.

State licensure adds a geographic layer: a dermatologist must generally be licensed in the state where the patient is located at the time of service, not merely where the provider's primary office is located. The Federation of State Medical Boards (FSMB) maintains an Interstate Medical Licensure Compact (IMLC) that 37 states, the District of Columbia, and Guam had joined as of its published membership roster, easing multi-state practice for qualifying physicians (FSMB Interstate Medical Licensure Compact).

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)